CNS Pharmaceuticals, Inc. 是一家临床制药公司,致力于开发用于治疗脑部和中枢神经系统肿瘤的候选抗癌药物。公司总部位于德克萨斯州休斯顿。
财务指标
营业收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
营业支出
2026-06-30
$270万
2026-03-31
$497.33万
2025-12-31
$598.9万
2025-09-30
$325.26万
净利润
2026-06-30
-$258.8万
2026-03-31
-$493.7万
2025-12-31
-$595.58万
2025-09-30
-$321.84万
净利润率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
每股收益
2026-06-30
$-0.38
2026-03-31
$-7.30
2025-12-31
$-10.15
2025-09-30
$-5.76
息税折旧摊销前利润
2026-06-30
-$257.28万
2026-03-31
-$492.9万
2025-12-31
-$595.2万
2025-09-30
-$321.56万
有效税率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
项目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
营业收入
$0
$0
$0
$0
营业支出
$270万
$497.33万
$598.9万
$325.26万
净利润
-$258.8万
-$493.7万
-$595.58万
-$321.84万
净利润率
--
--
--
--
每股收益
$-0.38
$-7.30
$-10.15
$-5.76
息税折旧摊销前利润
-$257.28万
-$492.9万
-$595.2万
-$321.56万
有效税率
--
--
--
--
常见问题
CNSP is the ticker symbol for CNS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company. Shares of CNSP trade on the Nasdaq Capital Market under that ticker. The company focuses on developing treatments for brain and central nervous system cancers, including glioblastoma. Because it is a small clinical-stage company, CNSP's stock is often followed by investors interested in speculative, development-stage biotech names. For the latest company-specific details and current listing information, refer to the CNSP quote page.
Recent price action for CNSP can be seen in the performance chart and returns data displayed on this page. As a small-cap biotech, CNSP's shares may move sharply around trial updates, financing news, or broader market sentiment toward speculative stocks. Rather than relying on a single snapshot, review the latest CNSP price, daily change, and period returns shown above for the most current picture. Historical price data is available through the chart tools on this page.
Evaluating CNSP's valuation typically involves looking beyond standard earnings-based ratios, since clinical-stage biotechs often have little or no revenue or earnings. Investors may review cash balances, research and development spending, share count, and pipeline progress. The current market capitalization shown on this page provides one reference point. For a fuller view, compare CNSP's market value and financial position against its stage of development, rather than applying mature-company valuation multiples directly.
CNSP can generally be bought through a brokerage account that offers U.S. stock trading. You would search for the ticker CNSP on your broker's platform and place a buy order, choosing order type and quantity. Availability may depend on your broker and account type. Confirm any commissions, fees, and order requirements with your brokerage. Before trading, check the latest CNSP quote, spread, and volume displayed on this page to understand current market conditions.
Analyzing CNSP's financial performance usually starts with its quarterly and annual reports, including the income statement, balance sheet, and cash flow statement. Key items for a clinical-stage biotech include cash and equivalents, operating expenses, research and development costs, and net loss. These figures help assess how long the company can fund operations. The earnings and financials sections on this page provide CNSP's reported results and filing links for detailed review.
CNSP faces risks common to clinical-stage biopharmaceutical companies. These include the possibility that drug candidates fail in trials or fail to gain regulatory approval, heavy dependence on successful study outcomes, and the need to raise additional capital, which can dilute existing shareholders. Small-cap stocks like CNSP may also trade with lower liquidity and higher price volatility. Review CNSP's risk factors in its SEC filings and the latest company updates for a complete picture.